The differences in bladder cancer outcomes between the sexes has again been highlighted.
Uncommon among cancers, bladder cancer outcomes are notably worse for women than for …

The global incidence of bladder cancer is more than half a million diagnoses each year.
Bladder cancer can be categorized into non-muscle-invasive bladder cancer (NMIBC) …

Understanding the molecular landscape of nonmuscle-invasive bladder cancer (NMIBC) is
essential to improve risk assessment and treatment regimens. We performed a …

Abstract Purpose: From 8% to 28% of patients with papillary thyroid carcinoma (PTC)
experience recurrence, complicating risk stratification and treatment. We previously …

Abstract Background Bladder cancer (BCa) has a high incidence and recurrence rate
worldwide. So far, there is no noninvasive detection of BCa therapy and prognosis based on …

Background: The therapeutic gold standard for patients with high-risk non-muscle invasive
bladder cancer (NMIBC) is intravesical therapy with Bacillus Calmette-Guérin (BCG) …

Bladder cancer (BC) is the fifth most common malignancy in humans and has poor survival
rates. Although there is extensive research on the diagnosis and treatment of BC, novel …

BACKGROUND: Smoking is one of the most popular risk factors provoking bladder cancer
(BC). This research intended to estimate cigarette smoking effect involving PAF signs …

Non–muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease categorized as
low, intermediate, high, or very high risk, for which recurrence and progression rates and …

Bladder cancer is a commonly diagnosed cancer, especially in men, and 70% of new
diagnoses are considered non-muscle invasive bladder cancer (NMIBC). Bladder cancer is …